In: NEOPLASMA, vol. 60, no. 6
O. Fiala - M. Pešek - J. Finek - J. Krejci - L. Havel - M. Hrnciarik - F. Salajka - Z. Bortlicek - L. Benesova - M. Minarik
Detaily:
Rok, strany: 2013, 676 - 682
O článku:
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib’s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P Keywords: squamous cell, NSCLC, erlotinib, targeted treatment, EGFR-TKI
Ako citovať:
ISO 690:
Fiala, O., Pešek, M., Finek, J., Krejci, J., Havel, L., Hrnciarik, M., Salajka, F., Bortlicek, Z., Benesova, L., Minarik, M. 2013. Erlotinib in the treatment of advanced squamous cell NSCLC. In NEOPLASMA, vol. 60, no.6, pp. 676-682. 0028-2685.
APA:
Fiala, O., Pešek, M., Finek, J., Krejci, J., Havel, L., Hrnciarik, M., Salajka, F., Bortlicek, Z., Benesova, L., Minarik, M. (2013). Erlotinib in the treatment of advanced squamous cell NSCLC. NEOPLASMA, 60(6), 676-682. 0028-2685.